Total Revenue [USD, Millions]

Cost of Goods Sold (COGS) [USD, Millions]

SG&A [USD, Millions]

R&D [USD, Millions]

D&A [USD, Millions]

Interest Expense [USD, Millions]

Operating Income (EBIT) [USD, Millions]

Net Income [USD, Millions]

EPS - Basic [USD, Per Share]

EPS - Diluted [USD, Per Share]

7b1ac7460184edb8a3880908d0885500602f08bd087441ebb5ebd155a030c9be

Current Assets [USD, Millions]

Cash and Cash Equivalents [USD, Millions]

Accounts Receivable [USD, Millions]

Inventory [USD, Millions]

Non-Current Assets [USD, Millions]

PP&E [USD, Millions]

Goodwill [USD, Millions]

Intangible Assets [USD, Millions]

Current Liabilities [USD, Millions]

Accounts Payable [USD, Millions]

Short-term Debt [USD, Millions]

Accrued Expenses [USD, Millions]

Non-Current Liabilities [USD, Millions]

Long-term Debt [USD, Millions]

Lease Liabilities [USD, Millions]

Deferred Tax Liabilities [USD, Millions]

Shareholders' Equity [USD, Millions]

Retained Earnings [USD, Millions]

Common Stock [USD, Millions]

Additional Paid-in Capital [USD, Millions]

ab4416538e9e3e73b0d50d4beeb8c1a2dc782385317e33385fac4988e319966d

Imaging

- Radiology

- Interventional Guidance

Ultrasound

- Procedural Guidance

- Specialized Ultrasound

Patient Care Solutions

- Monitoring Solutions

- Life Support Solutions

Pharmaceutical Diagnostics

Other

Total Revenue

d0807ef378d8f04b5c37b588fcbfc8bbc2a538bb30c880523e895dbaeda0ac88

Adjustments for Non-Cash Items

Stock-Based Compensation

Changes in Working Capital

Capital Expenditures (CapEx)

Proceeds from / Repayments of Debt

Share Repurchases

Dividend Payments

Net Change in Cash

3bfad9f96afdb390b849bbecc0c5097919c9e2423f1e644bd3954a8845a84e16

United States and Canada

- United States

Europe, Middle East, Africa

China region

- China

Rest of World

- All other countries

6a2cf432314949d3f2479465c01ff32c9e671e6213f5d61c6ed9a74a941f24a8

Organic revenue for Imaging (USD millions)

Organic revenue for AVS (USD millions)

Organic revenue for Patient Care Solutions (USD millions)

Organic revenue for Pharmaceutical Diagnostics (PDx) (USD millions)

Organic revenue for Other (USD millions)

Total organic revenue (USD millions)

Remaining Performance Obligations (USD millions)

Free cash flow (USD millions)

5eb156a674443f54a22cfd7973be66d4c171c69b3200d4f166024d38b4043519

Cash, cash equivalents, and restricted cash (USD, millions)

Receivables – net (USD, millions)

Due from related parties (USD, millions)

Inventories (USD, millions)

Contract and other deferred assets (USD, millions)

All other current assets (USD, millions)

Current assets (USD, millions)

Property, plant, and equipment – net (USD, millions)

Goodwill (USD, millions)

Other intangible assets – net (USD, millions)

Deferred income taxes (Assets) (USD, millions)

All other assets (USD, millions)

Total assets (USD, millions)

Short-term borrowings (USD, millions)

Accounts payable (USD, millions)

Due to related parties (USD, millions)

Contract liabilities (USD, millions)

All other current liabilities (USD, millions)

Current liabilities (USD, millions)

Long-term borrowings (USD, millions)

Compensation and benefits (USD, millions)

Deferred income taxes (Liabilities) (USD, millions)

All other liabilities (USD, millions)

Total liabilities (USD, millions)

Redeemable noncontrolling interests (USD, millions)

Common stock (USD, millions)

Additional paid-in capital (USD, millions)

Retained earnings (USD, millions)

Accumulated other comprehensive income (loss) – net (USD, millions)

Total equity attributable to GE HealthCare (USD, millions)

Noncontrolling interests (USD, millions)

Total equity (USD, millions)

Total liabilities, redeemable noncontrolling interests, and equity (USD, millions)

d605380be1e1110424948dfa4ad3d1284cba28b46a5aacbaaf73b28f06ab1926

The documents note that **short-term borrowings** increased from **$15 million as of December 31, 2022** to **$1,006 million as of December 31, 2023**, but they do not provide any specific reasons for this significant change.  **[0001932393-24-000015_release4q23earnings.htm:4]** **[0001932393-24-000017_release4q23earnings.htm:5]** **[0001932393-24-000012_release4q23earnings.htm:4]** 

Why did Short-term borrowings spike in Q4 2023?

The reduction in **Long-term borrowings** in Q4 2023 appears to be primarily linked to the company's debt repayment activity, as it repaid **$850 million** during Q4 2023 and an additional **$150 million** in January 2024.  **[0001932393-24-000015_release4q23earnings.htm:0]** **[0001932393-24-000012_release4q23earnings.htm:0]** 

What led to the reduction in Long-term borrowings in Q4 2023?

The **significant decrease** in inventories during **Q4 2023** was mainly driven by improved **supplier lead times and inventory management**, which led to **higher inventory turns** and a reduction in aged inventory balances. The company implemented **lean supply chain measures**—including safety stock reduction and optimized stock planning—that played a key role in lowering inventory levels. Additionally, operational improvements across all segments contributed to the overall decline in inventories, which decreased by **$195 million** year-over-year.  **[GEHC_3371994_4]** **[0001932393-24-000013_gehc-20231231.htm:173]** 

Why did Inventories decrease significantly in Q4 2023?

The rise in **Current liabilities** in Q4 2023 was primarily driven by a significant increase in **short-term borrowings** from **$15 million** to **$1,006 million**, and a notable increase in **all other current liabilities** from **$2,190 million** to **$3,011 million**. There was also a slight increase in **contract liabilities** from **$1,896 million** to **$1,918 million**, although this had a smaller impact overall. These changes resulted in a total increase of **$1,790 million** in current liabilities.  **[0001932393-24-000015_release4q23earnings.htm:4]** 

What drove the rise in Current liabilities in Q4 2023?

The **Other intangible assets – net** declined in Q4 2023 from **$1,520 million** at the end of 2022 to **$1,253 million** at the end of 2023. While the documents do not provide concrete reasons, this change is typically due to factors such as **amortization, impairment charges, or disposals**. In this case, the **amortization of intangible assets for 2023 was $362 million**, which likely contributed to the decline.  **[0001932393-24-000017_release4q23earnings.htm:5]** **[0001932393-24-000013_gehc-20231231.htm:116]** 

Why did Other intangible assets decline in Q4 2023?

74136353f10b088d8b0409f8d32eab390f98e3a41551d67d467544a311af0241

GE Healthcare Technologies Inc (GEHC)

Financials